Duke Street Bio receives FDA fast track designation for PARP1-selective inhibitor with CNS activity

Addresses brain metastases harboring BRCA1/2 and/or HRR alterations—an area of high unmet need

AB Science receives FDA and EMA authorization for phase 3 Trial of prostate cancer treatment

Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments

EMA and HMA to strengthen Anti-D Immunoglobulin supply chain

These medicines are essential in preventing RhD immunisation during pregnancy

Godavari Biorefineries' anti-cancer patent now validated in Spain and UK

Anti-cancer patent now validated in Spain, the UK, and as a Unitary Patent covering multiple EU member states

Biocon Biologics receives MHRA UK approval for Vevzuo and Evfraxy, Denosumab Biosimilars

Vevzuo is authorized for the prevention of skeletal related events in adults with advanced malignancies involving bone

GACL flags of first dispatch of Benzyl Alcohol and Benzaldehyde

The facility will manufacture 13,200 MTPA Benzyl Chloride, 9,600 MTPA Benzyl Alcohol, and 7,200 MTPA Benzaldehyde

Yatharth Hospitals names Ashutosh Kumar Jha as Group Chief – Strategy, M&A, and Investor Relations

Zota Health Care expands Davaindia network to 1,760 operational stores

Surpassing 1,000 Company Owned Company Operated stores

Alembic Pharmaceuticals acquires Utility Therapeutics for $12 million to strengthen US footprint

The acquisition of Pivya is an important step in Alembic’s ability to provide branded pharmaceutical product to the US Healthcare market

Asahi Kasei Pharma starts Phase III study of promising CIPN prevention therapy

ART-123 is a recombinant human thrombomodulin approved in Japan in 2008